Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Enrichment of CES1 Carriers in the Pharmacogenomics Anti-Platelet Intervention Study

Next Previous
Trial Profile

Enrichment of CES1 Carriers in the Pharmacogenomics Anti-Platelet Intervention Study

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 Oct 2018

At a glance

  • Drugs Aspirin (Primary) ; Clopidogrel (Primary)
  • Indications Acute coronary syndromes; Angina pectoris; Atherosclerosis; Cardiovascular disorders; Coronary thrombosis; Ischaemic heart disorders; Myocardial infarction; Peripheral arterial occlusive disorders; Stroke; Unstable angina pectoris
  • Focus Pharmacogenomic; Therapeutic Use

    • Most Recent Events

    • 09 Oct 2018 Planned initiation date changed from 1 Sep 2018 to 1 Mar 2019.
    • 10 Apr 2018 Planned initiation date changed from 1 Mar 2018 to 1 Sep 2018.
    • 24 Oct 2017 Planned initiation date changed from 1 Sep 2017 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top